Talaris Therapeutics, Inc. Announces $100M Series A Financing to Advance Its Novel, Allogeneic Cell Therapy Through Late-Stage Clinical Development
Home » Talaris Therapeutics, Inc. Announces $100M Series A Financing to Advance Its Novel, Allogeneic Cell Therapy Through Late-Stage Clinical Development
Talaris Therapeutics, Inc. Announces $100M Series A Financing to Advance Its Novel, Allogeneic Cell Therapy Through Late-Stage Clinical Development2019-04-182019-04-23http://redpeppermergers.com/wp-content/uploads/rpm-white-red-1.pngRedPepper Mergershttp://redpeppermergers.com/wp-content/uploads/rpm-white-red-1.png200px200px
VIEW ARTICLE If you would like to know more regarding the topic in this blog post, please do not hesitate to contact us.